Abstract |
The most common chronic nephropathy seen with human immunodeficiency virus ( HIV) infection is characterized by heavy proteinuria and rapid deterioration of renal function. We here report the findings in an HIV-seropositive patient with nephrotic-range proteinuria and biopsy-proven HIV-associated nephropathy treated with the angiotensin-converting enzyme ( ACE) inhibitor, fosinopril. During treatment periods, the patient demonstrated a significant decrement in 24-hour urinary protein excretion without change in renal function. The patient acted as her own control. After discontinuation of the drug, the 24-hour protein excretion deteriorated to pretreatment levels. ACE inhibition has been reported to decrease proteinuria and to have a beneficial influence on the progression of renal failure in diabetic and nondiabetic renal disease. To date, there is no known therapy for HIV-associated nephropathy. Our preliminary results in this patient suggest the need for long-term studies to assess whether this form of therapy can improve proteinuria over longer periods and, at the same time, ameliorate the progressive form of nephropathy seen in selected HIV-seropositive patients.
|
Authors | G C Burns, R Matute, D Onyema, I Davis, I Toth |
Journal | American journal of kidney diseases : the official journal of the National Kidney Foundation
(Am J Kidney Dis)
Vol. 23
Issue 3
Pg. 441-3
(Mar 1994)
ISSN: 0272-6386 [Print] United States |
PMID | 8128948
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
|
Topics |
- AIDS-Associated Nephropathy
(drug therapy)
- Adult
- Female
- Fosinopril
(therapeutic use)
- Humans
- Proteinuria
(drug therapy)
|